Jabra Enhance Plus vs Otofonix Groove

The Jabra Enhance Plus is a mid-priced OTC hearing aid priced at $799, earning a B grade with a SoundScore of 3.7/5 in our lab testing. This visible-in-ear device ranks #28 of 65 OTC hearing aids tested, placing it in the top 42% of its category. In our testing, the Enhance Plus demonstrated notable strengths in speech clarity and audio streaming. Speech in quiet scored a strong 4.2/5, measuring 1.36 points above the category average. Music streaming performance was equally impressive at 3.8/5, a full 1.88 points above average—making this a solid choice for users who prioritize phone audio streaming. Feedback handling was excellent at 4.7/5. However, the device has a significant weakness: own-voice comfort scored just 0.3/5, falling 2.21 points below the category average. This suggests pronounced occlusion effects that may make the user's own voice sound boomy or unnatural. Speech in noise performance was mixed at 2.1/5—above the category average by 0.62 points, but still limited in absolute terms for challenging listening environments. The Enhance Plus showed meaningful improvement with tuning, jumping from a normalized Initial Score of 3.6/5 to a Tuned Score of 4.2/5. Buyers should note that several competitors in the same price range score higher, including the Sony CRE-E10 at 4.66/5. This device is best suited for users who prioritize music streaming and speech clarity in quieter settings, and who can tolerate own-voice occlusion.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.